← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2007First marketed drug
Nov 15, 2024First NDA
Nov 15, 2024Last known activity
May 18, 2026
Timeline
2000s
- Jan 1, 2005
Syndax Pharmaceuticals— Founded
2020s
- Nov 15, 2024
Revumenib— NDA Organization
Drugs by trial phase (33 distinct, 49 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Indications
Studied for
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Breast Diseases
- Breast Neoplasms
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Endometrioid
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinosarcoma
- Cholangiocarcinoma
- Colorectal Neoplasms
- Coronavirus Infections
- Cystadenocarcinoma, Serous
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Gastrointestinal Neoplasms
- Graft vs Host Disease
- Hodgkin Disease
- Kidney Neoplasms
- Leukemia
- Leukemia, Biphenotypic, Acute
- Lung Diseases
- Lung Neoplasms
- Lymphoma
- Melanoma
- Mixed Tumor, Mullerian
- Neoplasm Metastasis
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Renal Insufficiency
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Triple Negative Breast Neoplasms
- Uveal Neoplasms
Marketed drugs (1)
Recent trials (50)
- NCT05918913Lead sponsorN/A—
- NCT07283640CollaboratorPhase 1May 18, 2026
- NCT07211958Lead sponsorPhase 3Dec 31, 2025
- NCT06313437CollaboratorPhase 1Sep 30, 2024
- NCT06284486CollaboratorPhase 2Sep 23, 2024
- NCT06229912CollaboratorPhase 2Jul 31, 2024
- NCT06226571Lead sponsorPhase 1May 21, 2024
- NCT06177067CollaboratorPhase 1Jan 31, 2024
- NCT06132256Lead sponsorPhase 2Nov 30, 2023
- NCT05731947Lead sponsorPhase 1/Phase 2Apr 4, 2023
- NCT05360160CollaboratorPhase 1/Phase 2Oct 14, 2022
- NCT05406817Study directorPhase 1Aug 5, 2022
- NCT05406817Lead sponsorPhase 1Aug 5, 2022
- NCT05326516Study directorPhase 1Mar 9, 2022
- NCT05326516Lead sponsorPhase 1Mar 9, 2022
Details
- Founded
- Waltham, MA, US Jan 1, 2005
- First NDA
- Nov 15, 2024
- Last known activity
- May 18, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy